


Supplementary Information

Supplementary Table S1. HCV infecting genotype and antiviral therapies for HIV and HCV in study participants

Study participant (#)	HCV genotype	HCV therapy	HIV antiretroviral therapy
1	3	SOF + DCV	2 NRTI + II
2	1b	SOF + SMV	2 NRTI + II
3	1a	SOF + DCV	2 NRTI + II
4	4	SOF + LDV	2 NRTI + II
5	1a	SOF + DCV	PI + NNRTI + II
6	1b	SOF + LDV	PI + II + MVC
7	4	SOF + LDV	NRTI + PI
8	1b	SOF + LDV	NNRTI + II
9	1b	SOF + LDV	2 NRTI + II
10	1a	3 DAAs (unspecified)	2 NRTI + II
11	4	SOF + DCV	2 NRTI + PI
12	1a	SOF + SMV	2 NRTI + II
13	1a	SOF + SMV	2 NRTI + II
14	1a	SOF + DCV	2 NRTI + PI
15	1a	SOF + DCV	2 NRTI + II
16	1a	SOF + SMV	2 NRTI + II
17	4	SOF + LDV	2 NRTI + II
18	4	SOF + LDV	2 NRTI + NNRTI
19	1a	SOF + LDV	2 NRTI + II
20	1a	SOF + SMV	2 NRTI + II
21	1a	SOF + LDV	NNRTI + II
22	1a	SOF + LDV	2 NRTI + NNRTI
23	4	SOF + LDV	2 NRTI + II
24	1a	SOF + DCV + SMV	2 NRTI + PI
25	3	SOF + DCV	2 NRTI + PI
26	1a	SOF + LDV	2 NRTI + NNRTI
27	1b	PEG-IFN α + RBV + PI	2 NRTI + NNRTI
28	1a	PEG-IFN α + RBV + PI	2 NRTI + PI
29	1a	PEG-IFN α + RBV + PI	2 NRTI + II
30	1a	PEG-IFN α + RBV + PI	2 NRTI + PI
31	1a	PEG-IFN α + RBV + PI	2 NRTI + PI
32	1b	PEG-IFN α + RBV + PI	2 NRTI + PI
33	1a	PEG-IFN α + RBV + PI	2 NRTI + II
34	1b	PEG-IFN α + RBV + PI	2 NRTI + NNRTI
35	3	PEG-IFN α + RBV	2 NRTI + NNRTI
36	1a	PEG-IFN α + RBV + PI	2 NRTI + II
37	1b	PEG-IFN α + RBV + PI	2 NRTI + II
38	MG	PEG-IFN α + RBV + PI	2NRTI + PI
39	1a	PEG-IFN α + RBV + PI	2 NRTI + II
40	1a	PEG-IFN α + RBV	2 NRTI + NNRTI

41	1a	PEG-IFN α + RBV + PI	2 NRTI + II
42	3	PEG-IFN α + RBV	2 NRTI + PI
43	1a	PEG-IFN α + RBV + PI	2 NRTI + NNRTI
44	1b	PEG-IFN α + RBV + PI	II + PI
45	IG	PEG-IFN α + RBV + PI	NRTI + PI
46	1b	PEG-IFN α + RBV + PI	2 NRTI + PI
47	1a	PEG-IFN α + RBV	2 NRTI + II
48	IG	PEG-IFN α + RBV + PI	2 NRTI + II
49	IG	PEG-IFN α + RBV + PI	2 NRTI + II
50	3	PEG-IFN α + RBV	2 NRTI + NNRTI
51	3	PEG-IFN α + RBV + SOF	2 NRTI + NNRTI
52	IG	PEG-IFN α + RBV + PI	2 NRTI + II
53	1a	PEG-IFN α + RBV + PI	2 NRTI + II
54	1a	PEG-IFN α + RBV + PI	2 NRTI + NNRTI
55	1b	PEG-IFN α + RBV + PI	2 NRTI + NNRTI
56	1a	PEG-IFN α + RBV + PI	2 NRTI + NNRTI
57	1b	PEG-IFN α + RBV + PI	2 NRTI + PI
58	1a	PEG-IFN α + RBV	2 NRTI + II
59	1b	PEG-IFN α + RBV + PI	2 NRTI + II
60	1b	PEG-IFN α + RBV + PI	2 NRTI + II
61	MG	PEG-IFN α + RBV + PI	2 NRTI + NNRTI
62	1b	PEG-IFN α + RBV + PI	2 NRTI + NNRTI
63	3	PEG-IFN α + RBV	2 NRTI + NNRTI
64	4	PEG-IFN α + RBV + PI	2 NRTI + PI
65	1a	PEG-IFN α + RBV + PI	2 NRTI + II
66	1b	PEG-IFN α + RBV + PI	2 NRTI + NNRTI
67	1a	PEG-IFN α + RBV + PI	2 NRTI + PI
68	1b	PEG-IFN α + RBV + PI	2 NRTI + NNRTI
69	1a	PEG-IFN α + RBV + PI	2 NRTI + NNRTI
70	3	PEG-IFN α + RBV	NRTI + NNRTI + II
71	1a	PEG-IFN α + RBV + PI	2 NRTI + II

Abbreviations: Study participants #1-26 are HIV/HCV-coinfected individuals who underwent treatment with IFN-free DAA therapy. Study participants #27-71 are HIV/HCV-coinfected individuals who received IFN α -based therapy. DAA = direct-acting antiviral; DCV = daclatasvir; HCV = hepatitis C virus; HIV = human immunodeficiency virus; IFN α = interferon alpha; IG = indeterminate HCV genotypes; II = integrase inhibitor; LDV = ledipasvir; MG = mixed HCV genotypes; MVC = maraviroc; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; Peg-IFN α = pegylated IFN α ; PI = protease inhibitor; RBV = ribavirin; SMV = simeprevir; SOF = sofosbuvir.



Supplementary Figure S1. Longitudinal trajectories of neutralization scores for individual participants. Neutralization scores measured at multiple time points are shown for each participant. Each line represents a single participant, connecting their neutralization score values over time.

Abbreviations: EOT = end of treatment.

Supplementary Table S2. Comparison of Neutralization Scores by HIV Group and HCV Treatment (IFN-based vs. IFN-free) in HIV/HCV-Coinfected Individuals.

HIV vs. HIV/HCV	aAMR (95%CI)	p-value	q-value
HCV therapy			
Baseline			
HIV vs. HIV/HCV with IFN-based therapy	0.22 (0.04; 0.40)	0.016	0.022
HIV vs. HIV/HCV with IFN-free therapy	0.33 (0.10; 0.56)	0.005	0.014
~ 1 yr after EOT			
HIV vs. HIV/HCV with IFN-based therapy	0.24 (0.07; 0.42)	0.007	0.014
HIV vs. HIV/HCV with IFN-free therapy	0.25 (0.04; 0.47)	0.022	0.022
~ 5 yrs after EOT			
HIV vs. HIV/HCV with IFN-based therapy	0.27 (0.10; 0.44)	0.002	0.012
HIV vs. HIV/HCV with IFN-free therapy	0.29 (0.04; 0.53)	0.021	0.022
Baseline LSM			
Baseline			
HIV vs. HIV/HCV with LSM ≤ 20 kPa	0.32 (0.12; 0.53)	0.002	0.004
HIV vs. HIV/HCV with LSM > 20 kPa	0.21 (0.02; 0.4)	0.032	0.038
~ 1 yr after EOT			
HIV vs. HIV/HCV with LSM ≤ 20 kPa	0.33 (0.14; 0.53)	0.001	0.003
HIV vs. HIV/HCV with LSM > 20 kPa	0.17 (-0.02; 0.35)	0.077	0.077
~ 5 yrs after EOT			
HIV vs. HIV/HCV with LSM ≤ 20 kPa	0.32 (0.13; 0.51)	0.001	0.003
HIV vs. HIV/HCV with LSM > 20 kPa	0.23 (0.03; 0.43)	0.023	0.035
Baseline HCV RNA viral load			
Baseline			
HIV vs. HIV/HCV with HCV RNA $\leq 850,000$ copies/mL	0.27 (0.02; 0.52)	0.032	0.033
HIV vs. HIV/HCV with HCV RNA $> 850,000$ copies/ mL	0.24 (0.06; 0.43)	0.010	0.018
~ 1 yr after EOT			
HIV vs. HIV/HCV with HCV RNA $\leq 850,000$ copies/ mL	0.31 (0.08; 0.54)	0.009	0.018
HIV vs. HIV/HCV with HCV RNA $> 850,000$ copies/ mL	0.19 (0.02; 0.37)	0.033	0.033
~ 5 yrs after EOT			
HIV vs. HIV/HCV with HCV RNA $\leq 850,000$ copies/ mL	0.34 (0.09; 0.6)	0.009	0.018
HIV vs. HIV/HCV with HCV RNA $> 850,000$ copies/ mL	0.23 (0.05; 0.4)	0.012	0.018
Baseline HCV genotype			
Baseline			
HIV vs. HIV/HCV with non-HCV Gt1	0.31 (0.11; 0.51)	0.002	0.006
HIV vs. HIV/HCV with HCV Gt1	0.24 (0.06; 0.43)	0.008	0.012
~ 1 yr after EOT			
HIV vs. HIV/HCV with non-HCV Gt1	0.28 (0.05; 0.52)	0.017	0.020
HIV vs. HIV/HCV with HCV Gt1	0.24 (0.06; 0.41)	0.007	0.012
~ 5 yrs after EOT			
HIV vs. HIV/HCV with non-HCV Gt1	0.16 (-0.11; 0.42)	0.245	0.245
HIV vs. HIV/HCV with HCV Gt1	0.31 (0.13; 0.49)	0.001	0.006
Nadir CD4⁺ T-cells			
Baseline			
HIV vs. HIV/HCV with ≤ 200 cells/mm ³	0.3 (0.11; 0.49)	0.002	0.009
HIV vs. HIV/HCV with > 200 cells/mm ³	0.17 (-0.04; 0.39)	0.114	0.114

~ 1 yr after EOT			
HIV vs. HIV/HCV with ≤ 200 cells/mm ³	0.26 (0.08; 0.44)	0.005	0.010
HIV vs. HIV/HCV with > 200 cells/mm ³	0.21 (0; 0.43)	0.052	0.062
~ 5 yrs after EOT			
HIV vs. HIV/HCV with ≤ 200 cells/mm ³	0.24 (0.07; 0.42)	0.007	0.011
HIV vs. HIV/HCV with > 200 cells/mm ³	0.34 (0.12; 0.57)	0.003	0.009
Baseline CD4⁺ T-cells			
Baseline			
HIV vs. HIV/HCV with ≤ 500 cells/mm ³	0.25 (0.05; 0.45)	0.015	0.015
HIV vs. HIV/HCV with > 500 cells/mm ³	0.27 (0.08; 0.46)	0.006	0.014
~ 1 yr after EOT			
HIV vs. HIV/HCV with ≤ 500 cells/mm ³	0.23 (0.05; 0.42)	0.015	0.015
HIV vs. HIV/HCV with > 500 cells/mm ³	0.26 (0.07; 0.45)	0.008	0.014
~ 5 yrs after EOT			
HIV vs. HIV/HCV with ≤ 500 cells/mm ³	0.29 (0.1; 0.48)	0.003	0.014
HIV vs. HIV/HCV with > 500 cells/mm ³	0.26 (0.06; 0.46)	0.009	0.014

Statistics: Data were calculated using GLMs with family (gamma) and link (log). Values are expressed as the AMR, aAMR, and 95% CI. Raw p-values and adjusted q-values (p-values corrected for multiple testing using the Benjamini and Hochberg false discovery rate procedure) are reported. Statistically significant results are emphasized in bold.

Abbreviations: 95%CI = 95% confidence interval; aAMR = adjusted arithmetic mean ratio; HCV = hepatitis C virus; HIV = human immunodeficiency virus; EOT = end of treatment; Yr = year; IFN= Interferon; HCV-RNA = Hepatitis C Virus Ribonucleic Acid.